JP2018535647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535647A5 JP2018535647A5 JP2018513423A JP2018513423A JP2018535647A5 JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5 JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- ile
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 108091008874 T cell receptors Proteins 0.000 claims 19
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 1
- 108010037618 HLA-C*08 antigen Proteins 0.000 claims 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000713810 Rat sarcoma virus Species 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022188263A JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218688P | 2015-09-15 | 2015-09-15 | |
| US62/218,688 | 2015-09-15 | ||
| PCT/US2016/050875 WO2017048593A1 (en) | 2015-09-15 | 2016-09-09 | T cell receptors recognizing hla-cw8 restricted mutated kras |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188263A Division JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535647A JP2018535647A (ja) | 2018-12-06 |
| JP2018535647A5 true JP2018535647A5 (enExample) | 2019-10-17 |
| JP7185524B2 JP7185524B2 (ja) | 2022-12-07 |
Family
ID=56985686
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513423A Active JP7185524B2 (ja) | 2015-09-15 | 2016-09-09 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
| JP2022188263A Active JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188263A Active JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10556940B2 (enExample) |
| EP (2) | EP3901169B1 (enExample) |
| JP (2) | JP7185524B2 (enExample) |
| KR (2) | KR20250117744A (enExample) |
| CN (2) | CN108350059B (enExample) |
| AU (3) | AU2016323017B2 (enExample) |
| DK (1) | DK3350213T3 (enExample) |
| ES (1) | ES2879287T3 (enExample) |
| IL (1) | IL257840B2 (enExample) |
| MX (1) | MX2018003062A (enExample) |
| SA (1) | SA518391109B1 (enExample) |
| SG (1) | SG10201913868XA (enExample) |
| WO (1) | WO2017048593A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2557123B (en) | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| EP4159751A1 (en) * | 2016-08-02 | 2023-04-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-kras-g12d t cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP3602053B1 (en) * | 2017-03-31 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of isolating neoantigen-specific t cell receptor sequences |
| AU2018269370B2 (en) * | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| MX2020003117A (es) * | 2017-09-20 | 2020-08-20 | Us Health | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| US11466071B2 (en) * | 2017-12-04 | 2022-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class I-restricted t cell receptors against mutated RAS |
| WO2019246286A1 (en) * | 2018-06-19 | 2019-12-26 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| WO2020037239A1 (en) | 2018-08-16 | 2020-02-20 | Neon Therapeutics, Inc. | T cell receptor constructs and uses thereof |
| AU2020211922B2 (en) * | 2019-01-22 | 2025-05-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II-restricted T cell receptors against RAS with G12R mutation |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2020210202A1 (en) * | 2019-04-11 | 2020-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| WO2021029046A1 (ja) * | 2019-08-14 | 2021-02-18 | 日本電気株式会社 | 情報処理装置、情報処理方法及び記録媒体 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| KR20220119439A (ko) | 2019-12-20 | 2022-08-29 | 인스틸 바이오 유케이 리미티드 | 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도 |
| BR112022015897A2 (pt) * | 2020-02-14 | 2022-10-18 | Us Health | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| CA3185483A1 (en) * | 2020-07-16 | 2022-01-20 | Noam LEVIN | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
| WO2022072760A1 (en) * | 2020-10-02 | 2022-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| IL305393A (en) | 2021-02-25 | 2023-10-01 | Alaunos Therapeutics Inc | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114920824B (zh) * | 2022-05-27 | 2023-12-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301017B2 (en) * | 2002-05-30 | 2007-11-27 | Kolesnick Richard N | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| DK1910521T3 (da) * | 2005-08-05 | 2011-02-07 | Helmholtz Zentrum Muenchen | Generering af allo-begrænsede, antigenspecifikke T-celler |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| AU2011304728A1 (en) * | 2010-09-20 | 2013-03-14 | Biontech Ag | Antigen-specific T cell receptors and T cell epitopes |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CA3114877C (en) * | 2011-09-15 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| ES2784261T3 (es) | 2014-11-26 | 2020-09-23 | Us Health | Receptores de células T anti-KRAS mutado |
-
2016
- 2016-09-09 ES ES16770408T patent/ES2879287T3/es active Active
- 2016-09-09 KR KR1020257025325A patent/KR20250117744A/ko active Pending
- 2016-09-09 DK DK16770408.9T patent/DK3350213T3/da active
- 2016-09-09 MX MX2018003062A patent/MX2018003062A/es unknown
- 2016-09-09 CN CN201680058891.3A patent/CN108350059B/zh active Active
- 2016-09-09 US US15/758,954 patent/US10556940B2/en active Active
- 2016-09-09 WO PCT/US2016/050875 patent/WO2017048593A1/en not_active Ceased
- 2016-09-09 EP EP21162567.8A patent/EP3901169B1/en active Active
- 2016-09-09 KR KR1020187010326A patent/KR102841067B1/ko active Active
- 2016-09-09 IL IL257840A patent/IL257840B2/en unknown
- 2016-09-09 CN CN202111083392.9A patent/CN115073583A/zh active Pending
- 2016-09-09 EP EP16770408.9A patent/EP3350213B1/en active Active
- 2016-09-09 SG SG10201913868XA patent/SG10201913868XA/en unknown
- 2016-09-09 JP JP2018513423A patent/JP7185524B2/ja active Active
- 2016-09-09 AU AU2016323017A patent/AU2016323017B2/en active Active
-
2018
- 2018-03-13 SA SA518391109A patent/SA518391109B1/ar unknown
-
2020
- 2020-01-10 US US16/739,310 patent/US11667692B2/en active Active
-
2021
- 2021-02-10 AU AU2021200833A patent/AU2021200833B2/en active Active
-
2022
- 2022-07-26 AU AU2022209229A patent/AU2022209229B2/en active Active
- 2022-11-25 JP JP2022188263A patent/JP7461445B2/ja active Active
-
2023
- 2023-05-01 US US18/310,141 patent/US20230406904A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273254B1 (en) | HLA type II-restricted T cell receptors against RAS | |
| JP2023159112A5 (enExample) | ||
| JP2017536825A5 (enExample) | ||
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2015535816A5 (enExample) | ||
| JP2015525208A5 (enExample) | ||
| ES2984937T3 (es) | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1 | |
| JP2021505136A5 (enExample) | ||
| JP2020534828A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| FI3294333T4 (fi) | Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit | |
| RS55822B1 (sr) | Terapijski peptidi | |
| JP2016503295A5 (enExample) | ||
| JP2017524372A5 (enExample) | ||
| KR20180016321A (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
| RU2018128215A (ru) | Антитела против mica | |
| JP2023550998A5 (enExample) | ||
| RU2016124670A (ru) | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения | |
| CN113527473A (zh) | 一种全人源单克隆抗体及其应用 | |
| JP7140403B2 (ja) | Ｌｉｇｈｔに結合する抗原結合分子 | |
| CN110194799A (zh) | 结合犬pd-1的抗犬pd-1抗体 | |
| JP2017536821A5 (enExample) | ||
| WO2024114830A1 (zh) | 一种针对新冠病毒rbd的广谱单克隆抗体、其制备方法及应用 | |
| CN112094348A (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| Zuo et al. | A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding |